Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer

Launched by YONSEI UNIVERSITY · Feb 18, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment called Trastuzumab Deruxtecan (often shortened to T-DXd) for women with advanced breast cancer that is hormone receptor-positive and has low levels of HER2. The main goal is to see if T-DXd can help these patients more than standard hormone therapy after they have already tried one type of hormone treatment and another medication called a CDK4/6 inhibitor. The study involves 141 women who will be randomly assigned to receive either T-DXd or a hormone therapy chosen by their doctor.

To be eligible for this trial, participants must be female, at least 19 years old, and have cancer that is not easily treated with surgery. They should also have already been treated with first-line hormone therapy and have specific test results showing low HER2 levels. Throughout the trial, participants will provide samples of their cancer tissue and blood to help researchers understand how well the treatment is working. The trial will monitor not only how long patients remain stable on their treatment but also their overall health and quality of life. This research is important because it aims to find better options for patients with this specific type of breast cancer.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Histologically or cytologically confirmed hormone receptor-positive advanced breast cancer patients
• • 1. Have recurrent, metastatic, or unresectable disease
• • 2. Have HER2-low expression status, defined as IHC 2+/ISH- or IHC 1+,with a validated assay by ASCO/CAP guidelines
• • 3. Have no previous history of HER2-positive breast cancer (IHC 3+ or ISH+) by ASCO/CAP guidelines
• • 4. The hormone receptor (HR) status is defined by ER/PR IHC nuclear staining, and ER or PgR ≥1% is defined as hormone receptor-positive status
• • 2. Patients who progressed on 1st line endocrine + CDK4/6 inhibitor therapy for advanced breast cancer and received no other systemic therapy for advanced breast cancer. The all FDA-approved CDK4/6 inhibitors (palbociclib, ribociclib, and Abemaciclib) are allowed, and combination with aromatase inhibitors or fulvestrant are both allowed.
• • 3. Patients who have received chemotherapy or adjuvant endocrine therapy in the neo-adjuvant or adjuvant setting are eligible.
• • 4. Female patients with ≥19 years of age
• • 5. Radiologic or objective evidence of disease progression on or after the last systemic therapy prior to starting study treatment
• • 6. Patients must have at least one measurable lesion by RECIST 1.1 criteria, which was not previously irradiated or showed objective progression after irradiation to that lesion
• • 7. Patients must have an adequate tumor tissue sample available for assessment of HER2 by central laboratory and other exploratory biomarker analyses
• • 8. Patients with ECOG performance status 0 or 1
• • 9. Both pre- and post-menopausal patients are eligible, and pre-menopausal patients should receive ovarian function suppression treatment (GnRH agonist injection or surgical bilateral oophorectomy) while receiving fulvestrant or aromatase inhibitor treatment in the control arm.
• • 10. Adequate organ function for treatment Adequate organ and bone marrow function within 14 days before randomization/enrolment as described below:"
• • a) Haemoglobin: ≥ 9.0 g/dL NOTE: Participants requiring ongoing transfusions or growth factor support to maintain haemoglobin ≥9.0 g/dL are not eligible. (Red blood cell transfusion is not allowed within 1 week prior to C1D1) b) Serum albumin: ≥ 2.5 g/dL c) International normalised ratio or Prothrombin time and either partial thromboplastin or activated partial thromboplastin time: ≤ 1.5 × ULN d) Absolute neutrophil count (ANC) ≥1500 cells/mm3
• • granulocyte-colony stimulating factor administration is not allowed within 1 week prior to C1D1 ) e) Platelets ≥100,000 cells/mm3
• • Platelet transfusion is not allowed within 1 week prior to C1D1) f) Estimated creatinine clearance ≥50 mL/min, or serum creatinine \<1.5x institution upper limit of normal (ULN) g) Bilirubin≤1.5 x ULN
• • if no liver metastases or \< 3×ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia) or liver metastases at baseline h) AST (SGOT) ≤2.5 x ULN (5.0 x ULN if hepatic metastases) i) ALT (SGPT) ≤2.5 x ULN (5.0 x ULN if hepatic metastases)
• • 11. 12-Lead electrocardiogram (ECG) with normal tracing or non-clinically significant changes that do not require medical intervention
• • 12. QTc interval ≤470 msec and without history of Torsades de pointes based on average of the screening triplicate 12-lead ECG
• • 13. Pointes or other symptomatic QTc abnormality
• • 14. LVEF (by MUGA or echocardiogram) of ≥50% within 28 days before randomization/enrollment
• • 15. No history of pneumonitis other than radiation pneumonitis
• • 16. The patient has provided signed informed consent
• • 17. Neither pregnant or breastfeeding female patients
• • 18. Fertile women who are not in pregnancy or breastfeeding should use effective contraception for a period from two weeks before the start of research treatment, during treatment and up to seven months after last dose of study treatment
• 19. No other concurrent severe and/or uncontrolled medical disease which could compromise study participation, including any of the following:
• • 20. Adequate treatment washout period before enrollment are below -Major surgery ≥ 4 weeks -Radiation Therapy including palliative stereotactic radiation therapy to chest ≥ 4 weeks -Palliative stereotactic radiation therapy to other anatomic areas including whole brain radiation ≥ 2 weeks -Anti-Cancer chemotherapy \[Immunotherapy (non-antibody based therapy)\], retinoid therapy, hormonal therapy ≥ 3 weeks -Antibody based anti-cancer therapy ≥ 4 weeks -Targeted agents and small molecules ≥ 2 weeks or 5 half-lives, whichever is longer -Nitrosoureas or mitomycin C ≥ 6 weeks -Chloroquine/Hydroxychloroquine ≥ 14 days -Cell-free and CART, peritoneal shunt or drainage of pleural effusion, ascites or pericardial effusion ≥ 2 weeks prior to screening assessment
• Exclusion Criteria:
• • 1. Previous history of T-DXd or Dato-Dxd treatment for advanced breast cancer
• • 2. Severe Cardiac disease (e.g., uncontrolled hypertension, congestive cardiac failure, ventricular arrhythmias, active ischemic heart disease, myocardial infarction within the past year, Left Ventricular Ejection Fraction (LVEF) \> grade 2)
• • 3. Patients with a medical history of myocardial infarction (MI) within 6 months before randomization/enrolment, symptomatic congestive heart failure (CHF) (New York Heart Association Class II to IV), Subjects with troponin levels above ULN at screening (as defined by the manufacturer), and without any myocardial related symptoms, should have a cardiologic consultation before enrollment to rule out MI.
• • 4. Current active hepatic or biliary disease (except for Gilbert syndrome, asymptomatic gallstones, liver metastasis or stable chronic liver disease per investigator assessment)
• • 5. Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals
• • 6. Receipt of live, attenuated vaccine (mRNA and replication deficient adenoviral vaccines are not considered attenuated live vaccines) within 30 days prior to the first dose of T-DXd.
• • 7. Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade ≤ 1 or baseline.
• Note: Subjects may be enrolled with chronic, stable Grade 2 toxicities (defined as no worsening to \>Grade 2 for at least 3 months prior to \[randomization/enrollment/Cycle 1 Day 1\] and managed with standard of care treatment) that the investigator deems related to previous anticancer therapy, such as:
• • Chemotherapy-induced neuropathy
• • Fatigue
• * Residual toxicities from prior IO treatment: Grade 1 or Grade 2 endocrinopathies which may include:
• • 1. Hypothyroidism/hyperthyroidism
• • 2. Type 1 diabetes
• • 3. Hyperglycaemia
• • 4. Adrenal insufficiency
• • 5. Adrenalitis
• • 6. Skin hypopigmentation (vitiligo)
• • 8. Lung-specific intercurrent clinically significant illnesses including, but not limited to, any underlying pulmonary disorder (i.e., pulmonary emboli within three months prior to study enrollment, severe asthma, severe chronic obstructive pulmonary disorder \[COPD\], restrictive lung disease, significant pleural effusion etc.), and any autoimmune, connective tissue or inflammatory disorders with pulmonary involvement (i.e.,rheumatoid arthritis, Sjogren's syndrome, sarcoidosis etc.), and/or prior pneumonectomy.
• • 9. Has as a history of (non-infectious) ILD/ pneumonitis, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.Presence of spinal cord compression, symptomatic CNS metastases, or CNS metastases that require local CNS-directed therapy (such as radiotherapy or surgery). Patients with treated brain metastases should be neurologically stable (for 4 weeks post treatment and prior to study enrollment) and without steroid therapy over physiologic dose (\> 10mg prednisolone/day) for at least 2 weeks before administration of study drug.
• • 10. Significantly altered mental status prohibiting the understanding of the study, or with psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
• • 11. Active primary immunodeficiency, known human immunodeficiency virus (HIV) infection, or active hepatitis B or C infection. Subjects with past or resolved hepatitis B virus (HBV) infection who are anti-HBc positive (+) are eligible only if they are HBsAg negative (-). Patients positive for hepatitis C antibody are eligible only if polymerase chain reaction is negative for HCV RNA. Subjects should be tested for HIV prior to randomization/enrollment if required by local regulations or institutional review board (IRB)/ethics committee (EC).
• • 12. Multiple primary malignancies within 5 years, except adequately resected non-melanoma skin cancer, curatively treated in-situ disease, other solid tumors curatively treated, or contralateral breast cancer.
• • 13. Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.
• • 14. Pregnant or breast-feeding women.
• • 15. Previous allogeneic bone marrow transplant.
• • 16. Patients with a known hypersensitivity to T-DXd
• • 17. History of severe hypersensitivity reactions to other monoclonal antibodies
• • 18. Prior treatment with antibody drug conjugate that comprised an exatecan derivative that is a topoisomerase I inhibitor